Agios Pharm
$ 27.16
-3.07%
29 Dec - close price
- Market Cap 1,583,803,000 USD
- Current Price $ 27.16
- High / Low $ 28.00 / 27.05
- Stock P/E N/A
- Book Value 22.04
- EPS -6.80
- Next Earning Report 2026-02-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.28 %
- 52 Week High 46.00
- 52 Week Low 22.24
About
Agios Pharmaceuticals, Inc. is a leading biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of innovative therapies for oncology and rare genetic disorders by targeting cellular metabolism. With a robust pipeline and a commitment to precision medicine, Agios leverages its deep expertise in metabolic pathways to deliver transformative treatments that aim to improve patient outcomes. The company is also known for its strategic collaborations, which bolster its research and development initiatives, highlighting its dedication to advancing scientific knowledge and optimizing therapeutic strategies in complex disease areas.
Analyst Target Price
$36.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -1.78 | -1.93 | -1.55 | -1.74 | -1.47 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 | -1.47 | 0.67 |
| Estimated EPS | -1.91 | -1.75 | -1.76 | -1.63 | 7.91 | -1.6 | -1.65 | -1.65 | -1.7 | -1.56 | -1.7 | -1.62 |
| Surprise | 0.13 | -0.18 | 0.21 | -0.11 | -9.38 | -0.09 | 0.2 | -0.07 | 0.06 | 0.05 | 0.23 | 2.29 |
| Surprise Percentage | 6.8063% | -10.2857% | 11.9318% | -6.7485% | -118.5841% | -5.625% | 12.1212% | -4.2424% | 3.5294% | 3.2051% | 13.5294% | 141.358% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-12 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.96 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGIO
2025-12-27 16:09:28
The FDA has approved Agios Pharmaceuticals' AQVESME (mitapivat) for treating hemolytic anemia in adults with pyruvate kinase deficiency. This approval is based on two Phase 3 trials, ACTIVATE and ACTIVATE-T, which showed significant increases in hemoglobin and reductions in transfusion burden. AQVESME is the first and only approved therapy for this rare, lifelong genetic disease.
2025-12-26 18:29:39
Agios Pharmaceuticals (NASDAQ:AGIO) shares fell 5.3% on Friday, trading at $27.6350 on lower than average volume after opening at $27.55. Despite meeting quarterly EPS estimates and showing a 43.3% year-over-year revenue increase, the company remains unprofitable with a negative net margin of approximately 896%. Analyst ratings for AGIO are varied, with a consensus "Moderate Buy" and a $38.89 price target, although some analysts have recently cut their price objectives significantly.
2025-12-26 13:09:40
BofA Securities increased its price target for Agios Pharma (NASDAQ:AGIO) to $34.00 from $32.00, maintaining a Buy rating, following the FDA approval of its drug mitapivat (AQVESME). This drug is now the sole treatment approved for both transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia, leading BofA to raise its probability of success for thalassemia to 100%. The stock recently saw a 19.26% return, and the drug is anticipated to be available in late January 2026 with an expectation of $1 billion in peak sales.
2025-12-25 19:09:40
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) saw an 18.63% increase in its stock after receiving FDA approval for Aqvesme, its anemia treatment for patients with alpha or beta thalassemia. The drug is the only FDA-approved medicine for both non-transfusion-dependent and transfusion-dependent cases. While effective, the approval includes a Risk Evaluation and Mitigation Strategy (REMS) due to potential hepatocellular injury, requiring liver monitoring and specific patient, physician, and pharmacist certifications.
2025-12-25 18:09:47
Agios Pharmaceuticals (AGIO) received FDA approval for AQVESME (mitapivat) to treat anemia in adults with alpha- or beta-thalassemia, leading to a 14.6% stock increase. This first-in-class approval significantly de-risks the drug's near-term launch and transforms AQVESME into a new branded option in the thalassemia market. The company projects substantial revenue growth by 2028, with a fair value estimate suggesting a 10% upside to its current price, despite ongoing losses.
2025-12-25 11:09:03
BofA has increased its price target for Agios Pharmaceuticals (AGIO) shares to $34 from $32, while maintaining a Buy rating. This adjustment follows FDA approval for mitapivat, making it the only drug approved for both transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. The firm anticipates no significant impact on uptake from the REMS and black box warning for hepatocellular injury.
